LIVIVO - Search results -

Search results

Result 1 - 10 of total 98

Search options

Article ; Online: Anti-caries Streptococcus spp.: A potential preventive tool for special needs patients.

Mato, Eliane García / Montaño-Barrientos, Bitalio J / Rivas-Mundiña, Berta / Aneiros, Iván Varela / López, Lucía Sande / Posse, Jacobo Limeres / Lamas, Lucía Martínez

Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry

2023

Abstract: Introduction: Probiotics are living microorganisms that act on the host-microbiome interface to restore the microbiota's physiological homeostasis. Numerous probiotics have been marketed with inhibitory activity against Streptococcus mutans and ... ...

Abstract	Introduction: Probiotics are living microorganisms that act on the host-microbiome interface to restore the microbiota's physiological homeostasis. Numerous probiotics have been marketed with inhibitory activity against Streptococcus mutans and consequently with a potential anti-caries effect, mainly of the genera Lactobacillus and Bifidobacterium, whose main disadvantage is their limited ability to settle in the oral cavity. Methods: This narrative review describes the main Streptococcus spp. with probiotic anti-Streptococcus mutans activity, whose substantivity is greater than that of Lactobacillus spp. and consequently with anti-caries potentiality. We performed a literature review in the PubMed, Science Direct and Google Scholar databases of articles published in English (without time restriction) related to caries and probiotics. Results: The potential identified anti-caries probiotics included Streptococcus spp. A12, Streptococcus oralis (AJ3), Streptococcus oligofermentans, Streptococcus salivarius (K12, M18, JH, LAB813, 24SMB), Streptococcus spp. with arginolytic activity (S. sanguinis, S. gordonii, S. ratti, S. parasanguinis, S. intermedius, S. australis, and S. cristatus), Streptococcus rattus (JH145), Streptococcus dentisani and Streptococcus downii. Conclusions: The possibility of using these Streptococcus spp. as probiotics that inhibit the growth of dental plaque and the development of carious lesions represents a potential tool of particular interest for individuals with physical or intellectual disabilities that impede the routine and effective application of mechanical dental plaque removal techniques.
Language	English
Publishing date	2023-09-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	604118-8
ISSN	1754-4505 ; 0275-1879
ISSN (online)	1754-4505
ISSN	0275-1879
DOI	10.1111/scd.12920
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2515: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Mechanism of Action of

Martínez-Lamas, Lucía / García-Mato, Eliane / Rincón-Quintero, Anniris / Rivas-Mundiña, Berta / Diz-Dios, Pedro / Álvarez-Fernández, Maximiliano

Antibiotics (Basel, Switzerland)

2023 Volume 12, Issue 9

Abstract: Streptococcus ... ...

Abstract	Streptococcus downii
Language	English
Publishing date	2023-09-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics12091472
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Validation of a clinical decision tree to predict if a patient has a bacteraemia due to a β-lactamase producing organism.

Sousa, Adrian / Pérez-Rodríguez, María Teresa / Suarez, Milagros / Val, Nuria / Martínez-Lamas, Lucia / Nodar, Andrés / Crespo, Manuel

Infectious diseases (London, England)

2018 Volume 51, Issue 1, Page(s) 32–37

Abstract: Background: In recent years, several scores and algorithms have been developed in order to guide empirical antibiotic treatment in patients with gram-negative bacilli (GNB) bacteraemia according to the risk of extended-spectrum β-lactamase (BL) ... ...

Abstract	Background: In recent years, several scores and algorithms have been developed in order to guide empirical antibiotic treatment in patients with gram-negative bacilli (GNB) bacteraemia according to the risk of extended-spectrum β-lactamase (BL) producing. Some of these algorithms do not have easy applicability or present some limitations in their validation. The aim of our study was to validate a recently designed decision tree in our prospective cohort of bacteraemia due to gram-negative bacilli. Methods: We prospectively identified and analyzed all bacteraemia due to gram-negative bacilli in adult patients in our centre between January 2015 and December 2016. Previously developed clinical decision tree was used to classify patients in each of the terminal nodes. Patients were classified as BL group according to whether they were producers of any type of BL. The statistical power of the tree was analyzed by receiver operating characteristics (ROC) curve and by calculation of C-statistics. Results: A total of 448 episodes of bacteraemia were included; 132 (29.5%) were BL group; 68 (15.1%) ESBL producing, 43 (9.6%) due to AmpC and 21 (4.7%) isolates of Pseudomonas aeruginosa. The original clinical decision tree was modified according to the results of our multivariate analysis. The modified tree has a sensitivity of 71%, specificity of 92%, predictive positive value (PPV) of 79% and predictive negative value (NPV) of 88% generating an ROC curve with a C-statistic of 0.76. Conclusions: An easy-to-apply clinical decision tree could be used at the exact moment of diagnosis and adjust the empirical antibiotic treatment in patients with gram-negative bacilli bacteraemia.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Bacteremia/diagnosis ; Bacteremia/microbiology ; Decision Support Techniques ; Decision Trees ; Female ; Gram-Negative Bacteria/enzymology ; Gram-Negative Bacteria/isolation & purification ; Gram-Negative Bacterial Infections/diagnosis ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Male ; Middle Aged ; Prospective Studies ; ROC Curve ; Sensitivity and Specificity ; Young Adult ; beta-Lactam Resistance ; beta-Lactamases/metabolism
Chemical Substances	beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2018-10-29
Publishing country	England
Document type	Journal Article ; Observational Study ; Validation Studies
ZDB-ID	2839775-7
ISSN	2374-4243 ; 2374-4235
ISSN (online)	2374-4243
ISSN	2374-4235
DOI	10.1080/23744235.2018.1508883
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 600: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.

Sousa, Adrian / Pérez-Rodríguez, María Teresa / Soto, Adriana / Rodríguez, Lorena / Pérez-Landeiro, Antonio / Martínez-Lamas, Lucia / Nodar, Andrés / Crespo, Manuel

The Journal of antimicrobial chemotherapy

2018 Volume 73, Issue 11, Page(s) 3170–3175

Abstract: Background: Experience in real clinical practice with ceftazidime/avibactam is limited, and there are even fewer data on infections due to OXA-48-producing Enterobacteriaceae.: Methods: We designed an observational study of a prospectively collected ... ...

Abstract	Background: Experience in real clinical practice with ceftazidime/avibactam is limited, and there are even fewer data on infections due to OXA-48-producing Enterobacteriaceae. Methods: We designed an observational study of a prospectively collected cohort of adult patients receiving ceftazidime/avibactam in our centre. Only the first treatment course of each patient was analysed. Efficacy and safety were evaluated as 14 and 30 day mortality, recurrence rate at 90 days, resistance development and occurrence of adverse effects. Results: Fifty-seven patients were treated with ceftazidime/avibactam. The median age was 64 years (range 26-86), 77% were male and the median Charlson index was 3. The most frequent sources of infection were intra-abdominal (28%), followed by respiratory (26%) and urinary (25%). Thirty-one (54%) patients had a severe infection (defined as presence of sepsis or septic shock). Most patients received ceftazidime/avibactam as monotherapy (81%) and the median duration of treatment was 13 days. Mortality at 14 days was 14%. In multivariate analysis, the only mortality risk factor was INCREMENT-CPE score >7 (HR 11.7, 95% CI 4.2-20.6). There was no association between mortality and monotherapy with ceftazidime/avibactam. The recurrence rate at 90 days was 10%. Ceftazidime/avibactam resistance was not detected in any case and only two patients developed adverse events related to treatment. Conclusions: Ceftazidime/avibactam shows promising results, even in monotherapy, for the treatment of patients with severe infections due to OXA-48-producing Enterobacteriaceae and limited therapeutic options. The emergence of resistance to ceftazidime/avibactam was not observed.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/adverse effects ; Azabicyclo Compounds/therapeutic use ; Carbapenem-Resistant Enterobacteriaceae/drug effects ; Carbapenem-Resistant Enterobacteriaceae/enzymology ; Ceftazidime/adverse effects ; Ceftazidime/therapeutic use ; Drug Combinations ; Drug Resistance, Multiple, Bacterial ; Enterobacteriaceae Infections/drug therapy ; Enterobacteriaceae Infections/mortality ; Female ; Humans ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Prospective Studies ; Salvage Therapy ; beta-Lactamase Inhibitors/adverse effects ; beta-Lactamase Inhibitors/therapeutic use ; beta-Lactamases
Chemical Substances	Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; avibactam, ceftazidime drug combination ; beta-Lactamase Inhibitors ; Ceftazidime (9M416Z9QNR) ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2018-08-08
Publishing country	England
Document type	Journal Article ; Observational Study
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dky295
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CAN A MACHINE LEARNING ALGORITHM IDENTIFY SARS-COV-2 VARIANTS BASED ON CONVENTIONAL rRT-PCR? PROOF OF CONCEPT

cabrera Alvargonzalez, jorge / Larranaga Janeiro, Ana / Perez, Sonia / Martinez Torres, Javier / martinez lamas, Lucia / Davina Nunez, Carlos / Del Campo Perez, Victor / Suarez Luque, Silvia / Regueiro, Benito J / Porteiro Fresco, Jacobo

medRxiv

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been and remains one of the major challenges humanity has faced thus far. Over the past few months, large amounts of information have been collected that are only now beginning to be ... ...

Abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been and remains one of the major challenges humanity has faced thus far. Over the past few months, large amounts of information have been collected that are only now beginning to be assimilated. In the present work, the existence of residual information in the massive numbers of rRT-PCRs that tested positive out of the almost half a million tests that were performed during the pandemic is investigated. This residual information is believed to be highly related to a pattern in the number of cycles that are necessary to detect positive samples as such. Thus, a database of more than 20,000 positive samples was collected, and two supervised classification algorithms (a support vector machine and a neural network) were trained to temporally locate each sample based solely and exclusively on the number of cycles determined in the rRT-PCR of each individual. Finally, the results obtained from the classification show how the appearance of each wave is coincident with the surge of each of the variants present in the region of Galicia (Spain) during the development of the SARS-CoV-2 pandemic and clearly identified with the classification algorithm.
Keywords	covid19
Language	English
Publishing date	2021-11-15
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2021.11.12.21266286
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Proof of concept of the potential of a machine learning algorithm to extract new information from conventional SARS-CoV-2 rRT-PCR results.

Cabrera Alvargonzález, Jorge / Larrañaga Janeiro, Ana / Pérez Castro, Sonia / Martínez Torres, Javier / Martínez Lamas, Lucía / Daviña Nuñez, Carlos / Del Campo-Pérez, Víctor / Suarez Luque, Silvia / Regueiro García, Benito / Porteiro Fresco, Jacobo

Scientific reports

2023 Volume 13, Issue 1, Page(s) 7786

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been and remains one of the major challenges modern society has faced thus far. Over the past few months, large amounts of information have been collected that are only now beginning to be ... ...

Abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been and remains one of the major challenges modern society has faced thus far. Over the past few months, large amounts of information have been collected that are only now beginning to be assimilated. In the present work, the existence of residual information in the massive numbers of rRT-PCRs that tested positive out of the almost half a million tests that were performed during the pandemic is investigated. This residual information is believed to be highly related to a pattern in the number of cycles that are necessary to detect positive samples as such. Thus, a database of more than 20,000 positive samples was collected, and two supervised classification algorithms (a support vector machine and a neural network) were trained to temporally locate each sample based solely and exclusively on the number of cycles determined in the rRT-PCR of each individual. Overall, this study suggests that there is valuable residual information in the rRT-PCR positive samples that can be used to identify patterns in the development of the SARS-CoV-2 pandemic. The successful application of supervised classification algorithms to detect these patterns demonstrates the potential of machine learning techniques to aid in understanding the spread of the virus and its variants.
MeSH term(s)	Humans ; SARS-CoV-2/genetics ; COVID-19/diagnosis ; Reverse Transcriptase Polymerase Chain Reaction ; Algorithms ; Machine Learning ; COVID-19 Testing
Language	English
Publishing date	2023-05-13
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-023-34882-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.

Pérez-Lamas, Lucía / de Paz Arias, Raquel / Díaz, Rosa Mª Ayala / Montero, Luis Felipe Casado / Payer, Ángel Ramírez / Sierra, Magdalena / Marín, Francisca Ferrer / López, Raúl Pérez / Cirici, Blanca Xicoy / Steegmann, Juan Luis / Gómez Casares, María Teresa / Martínez-López, Joaquín / García-Gutiérrez, Valentín

Annals of hematology

2024

Abstract: In the field of chronic myeloid leukemia (CML), new strategies are needed to increase the rate of successful treatment discontinuations, a crucial goal in this disease. Anti-PD-L1 checkpoint inhibitors are a promising therapeutic approach in CML after ... ...

Abstract	In the field of chronic myeloid leukemia (CML), new strategies are needed to increase the rate of successful treatment discontinuations, a crucial goal in this disease. Anti-PD-L1 checkpoint inhibitors are a promising therapeutic approach in CML after the demonstration of an increase of these inhibitory molecules in patients with CML. A phase Ib/II (NCT04793399, registration date March 11, 2021) open-label exploratory trial has been conducted to evaluate the safety of atezolizumab, a humanized anti-PD-L1 antibody, in combination with bosutinib in patients with newly diagnosed chronic phase CML. A total of 36 patients were planned to be enrolled, but the study had to be prematurely terminated due to safety concerns. Nine patients were included in the study, and only 8 went on to receive the combination with atezolizumab. There were a total of 44 adverse events (AEs) during the study period. The most frequent were gastrointestinal (50%), mostly mild (86% grade 1-2). The most serious AEs were hepatic. There were 17 hepatic AEs in 5 patients. Of the hepatic AEs 5 were during the bosutinib monotherapy phase and 12 during the combination phase (AST increase x4, ALT increase x4, blood bilirubin increase x1, alkaline phosphatase elevation x2, GGT increase x2), most of them grade 3-4. There were 2 patients who presented a dose-limiting toxicity; a grade 3 elevation of transaminases, that led to premature termination of the study. The combination of atezolizumab with bosutinib presents hepatotoxicity as a dose-limiting effect and therefore we do not recommend to explore this combination in future studies.
Language	English
Publishing date	2024-04-03
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1064950-5
ISSN	1432-0584 ; 0939-5555 ; 0945-8077
ISSN (online)	1432-0584
ISSN	0939-5555 ; 0945-8077
DOI	10.1007/s00277-024-05662-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Streptococcus downii

Martínez-Lamas, Lucía / Limeres-Posse, Jacobo / Diz-Dios, Pedro / Álvarez-Fernández, Maximiliano

International journal of systematic and evolutionary microbiology

2020 Volume 70, Issue 7, Page(s) 4098–4104

Abstract: A new α-haemolytic streptococcal strain has been isolated from the dental plaque of a teenager with Down syndrome. Genetic and taxonomic analyses place ... ...

Abstract	A new α-haemolytic streptococcal strain has been isolated from the dental plaque of a teenager with Down syndrome. Genetic and taxonomic analyses place this
MeSH term(s)	Adolescent ; Bacterial Typing Techniques ; Base Composition ; DNA, Bacterial/genetics ; Dental Plaque/microbiology ; Down Syndrome ; Fatty Acids/chemistry ; Humans ; Mouth/microbiology ; Nucleic Acid Hybridization ; Phylogeny ; RNA, Ribosomal, 16S/genetics ; RNA, Ribosomal, 23S/genetics ; Sequence Analysis, DNA ; Streptococcus/classification ; Streptococcus/isolation & purification
Chemical Substances	DNA, Bacterial ; Fatty Acids ; RNA, Ribosomal, 16S ; RNA, Ribosomal, 23S
Language	English
Publishing date	2020-06-15
Publishing country	England
Document type	Journal Article
ZDB-ID	2002336-4
ISSN	1466-5034 ; 1466-5026
ISSN (online)	1466-5034
ISSN	1466-5026
DOI	10.1099/ijsem.0.004180
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 409: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.

Suárez, Milagros / Pérez-Landeiro, Antonio / Sanjurjo, Ana / Lima, Olalla / Sousa, Adrián / López, Ana / Martínez-Lamas, Lucía / Cabrera, Xurxo / Rubianes, Martín / Pérez-Rodríguez, María Teresa

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

2023 Volume 138, Page(s) 41–45

Abstract: Objectives: Due to its long half-life, dalbavancin offers benefits for long-duration treatments, especially osteoarticular and infective endocarditis (IE). We evaluated the efficacy and costs of IE treatment, comparing dalbavancin with standard of care ( ...

Abstract	Objectives: Due to its long half-life, dalbavancin offers benefits for long-duration treatments, especially osteoarticular and infective endocarditis (IE). We evaluated the efficacy and costs of IE treatment, comparing dalbavancin with standard of care (SOC). Methods: Retrospective multicenter cohort study of adult patients with Gram-positive cocci definite IE. Dalbavancin was used as a sequential therapy before discharge. Efficacy was a combined variable of clinical cure and absence of recurrence in 12-month follow-up. Length of hospital stay and the associated costs were analyzed in both groups of treatment. Results: Twenty-two patients received dalbavancin and 47 SOC. The efficacy was similar between the groups (dalbavancin 18 [72%] vs SOC 44 [94%], P = 0.198). Hospital stay was shorter in the dalbavancin group (dalbavancin 22 days [16-34] vs SOC 37 days [23-49], P = 0.001), especially in those with E. faecalis IE (dalbavancin 30 days [20-36] vs SOC 65 days [46-74], P <0.001). A reduction of cost was observed between both groups (dalbavancin, 12,206 € [8998-17,283] vs SOC 16,249 € [11,496-22,367], P = 0.032). Conclusion: Dalbavancin could be a safe and effective option in the sequential treatment of patients with IE. Also, a cost reduction was detected, due to a significant shortness of hospital stay.
MeSH term(s)	Adult ; Humans ; Anti-Bacterial Agents/adverse effects ; Cohort Studies ; Standard of Care ; Retrospective Studies ; Teicoplanin/adverse effects ; Endocarditis, Bacterial/drug therapy ; Endocarditis/drug therapy ; Costs and Cost Analysis
Chemical Substances	dalbavancin (808UI9MS5K) ; Anti-Bacterial Agents ; Teicoplanin (61036-62-2)
Language	English
Publishing date	2023-11-04
Publishing country	Canada
Document type	Multicenter Study ; Journal Article
ZDB-ID	1331197-9
ISSN	1878-3511 ; 1201-9712
ISSN (online)	1878-3511
ISSN	1201-9712
DOI	10.1016/j.ijid.2023.11.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4516: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Successful ceftazidime-avibactam therapy in a patient with multidrug-resistant Pseudomonas aeruginosa infective endocarditis.

Lima, Olalla / Sousa, Adrián / Filgueira, Antón / Otero, Antón / Cabaleiro, Andrea / Martinez-Lamas, Lucía / Vasallo, Francisco / Pérez-Rodríguez, M Teresa

Infection

2022 Volume 50, Issue 4, Page(s) 1039–1041

MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/pharmacology ; Azabicyclo Compounds/therapeutic use ; Ceftazidime/pharmacology ; Ceftazidime/therapeutic use ; Drug Combinations ; Drug Resistance, Multiple, Bacterial ; Endocarditis/drug therapy ; Humans ; Microbial Sensitivity Tests ; Pseudomonas Infections/drug therapy ; Pseudomonas aeruginosa
Chemical Substances	Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; avibactam, ceftazidime drug combination ; Ceftazidime (9M416Z9QNR)
Language	English
Publishing date	2022-04-17
Publishing country	Germany
Document type	Letter
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/s15010-022-01834-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito